Syphilis Rapid Test Market Projected to Reach USD 399.89 Million by 2034

The Syphilis Rapid Test Market is expanding as healthcare systems seek faster identification of infection in antenatal care, clinical services and outreach settings. Polaris Market Research values the market at USD 177.07 million in 2025, estimates USD 193.64 million in 2026 and projects USD 399.89 million by 2034, representing a CAGR of 8.39% during 2026–2034. The outlook reflects greater use of point-of-care syphilis testing and wider interest in bringing screening closer to patients.

Market Growth and Industry Outlook

Demand is linked to the need for timely screening and treatment, particularly where patients may face delays in accessing centralized laboratories. Expanded point-of-care syphilis testing can provide results during the same healthcare encounter, supporting clinical decisions without a separate laboratory visit. The report identifies the growing burden of congenital syphilis as a significant demand factor and connects procurement to public health responses. In this context, congenital syphilis screening remains a practical priority for maternal health services seeking earlier detection.

The industry outlook also reflects broader congenital syphilis screening and testing access. Products designed for settings with limited laboratory infrastructure allow public health organizations to organize screening through clinics, outreach programs and other approved venues. However, the expansion of eligible locations depends on local regulatory requirements, product authorization and operational fit, rather than rapid turnaround alone.

Key Market Drivers and Emerging Trends

Integrated infectious disease screening is becoming a notable product direction. The report highlights the World Health Organization’s July 2025 prequalification of the Determine Antenatal Care Panel, which brings HIV, hepatitis B and syphilis screening into a point-of-care package. Such multiplex rapid diagnostics can reduce the need to arrange separate infection-screening pathways during antenatal visits. These antenatal screening programs also create requirements for appropriate test performance, regulatory access and procurement planning.

Product development is also moving toward combined treponemal and non-treponemal antibody detection. Chembio submitted its DPP Syphilis TnT Assay for FDA review in January 2026, according to the report; the submission should not be confused with authorization. Meanwhile, volume-guarantee procurement has demonstrated potential to reduce certain test costs. These changes matter to purchasing teams evaluating both diagnostic functionality and the practical reach of their screening services.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/syphilis-rapid-test-market

Segment and Application Insights

Standalone syphilis-only rapid tests accounted for 55.82% of the test-type segment in 2025. Dual HIV/syphilis products represented 35.64%, while triple HIV/hepatitis B/syphilis testing is identified as the fastest-growing test format, with a projected 12.16% CAGR from 2026 to 2034. The figures illustrate a market accommodating both targeted and integrated screening needs rather than a single product model.

Fingerstick whole blood was the leading sample category, with a 62.48% share in 2025. Its minimal equipment needs make it relevant for antenatal screening programs and outreach environments. Among end users, hospitals and clinics accounted for 34.62% in 2025; antenatal care and public health programs represented 29.84%. The report identifies community-based testing as the fastest-growing end-user segment, with an 11.36% CAGR projected through 2034.

Regional Market Perspective

North America led the market in 2025 with a 31.42% share, supported by established antenatal, clinical and public health testing infrastructure. The report also describes ongoing efforts to broaden access in nontraditional healthcare settings. Europe accounted for 18.24% of the market in 2025, supported by diagnostic infrastructure and screening activity. Elsewhere, expansion of maternal screening, distribution capacity and availability of authorized tests are important conditions for adoption.

Competitive Landscape

Competition spans established diagnostic manufacturers and specialists in rapid testing. Reported participants include Abbott Diagnostics, SD Biosensor, Chembio Diagnostic Systems, Diagnostics Direct, bioLytical Laboratories, CTK Biotech and Trinity Biotech. Differentiation involves regulatory status, accuracy, specimen compatibility, ease of use, supply and testing-site suitability. For buyers, the availability of a recognized product is only one consideration; operational requirements and procurement terms also influence selection.

The report notes that limited U.S. availability of authorized decentralized point-of-care products constrains buyer choice. Manufacturers seeking additional channels must address regulatory and clinical performance requirements, while health programs must match procurement decisions to the types of locations where products can legally be used.

Future Market Outlook

The Syphilis Rapid Test Market outlook points to continued interest in integrated testing and faster access to screening. Broader availability of multiplex rapid diagnostics could support coordinated maternal health services, while community-based testing may extend service reach beyond conventional clinical facilities. Outcomes will remain tied to regulatory authorization, clinical performance, funding and distribution. The reported forecast therefore signals expanding demand, but not uniform adoption across product formats, purchasers or regions.

More Trending Latest Reports By Polaris Market Research:

Algae Oil Market

Organic Personal Care Products Market

Epdm Market

Virtual Reality (Vr) In Gaming Market

Organic Personal Care Products Market

Satellite Internet Market

Electric Motor Rotor Shaft Market

3D Motion Capture System Market

Benign Prostatic Hyperplasia Surgical Treatment Market